Report on recent progress of multiple myeloma in the 53rd annual meeting of American Society of Hematology
10.3760/cma.j.issn.1009-9921.2012.01.004
- VernacularTitle:多发性骨髓瘤治疗最新进展:第53届美国血液学会年会报道
- Author:
Min ZHAO
;
Xiaoyan QU
;
Lijuan CHEN
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Treatment;
ASH annual meeting
- From:
Journal of Leukemia & Lymphoma
2012;21(1):10-12
- CountryChina
- Language:Chinese
-
Abstract:
The 53rd ASH meeting was held in San Diego in December 2011. The meeting has received many advanced reports on the diagnosis and treatment of multiple myeloma (MM).On therapy,with the application of thalidomide, lenalidomide and bortezomib as inductive treatments, the clinical outcomeshave been improved greatly in MM patients.Pomalidomide,a new immunomodulator,can be hopefully used as a frontline medicine for MM because of its high response. Bendamustine combination with other treatments induced efficient response and good response rates in MM patients with renal insufficiency or relapsed/refactory disease. Currently autologous stem cell transplantation is still the standard care for newly diagnosed young MM patients.At this time other kinds of novel agents have entered into clinical trials and have shown a bright future of application.
